Weaver Kirke 4

4 · Organon & Co. · Filed Apr 2, 2026

AI-generated summary of this filing

Updated Apr 2, 2026

Organon (OGN) Gen. Counsel Weaver Kirke Receives RSU Award

What Happened

Weaver Kirke, General Counsel and Corporate Secretary of Organon & Co. (OGN), received a grant of 183,639 restricted stock units (RSUs) on March 31, 2026. The RSUs were awarded at $0.00 (grant of derivative securities) and will convert to common shares if/when they vest.
On the same date, previously granted RSUs vested/converted into shares: 6,201 and 12,312 shares were recorded as exercised/converted (derivative-to-share events). To satisfy tax withholding obligations, a total of 5,275 shares were surrendered (1,767 + 3,508) at the plan-required price of $5.70 per share, yielding tax withholdings of $10,072 and $19,996 respectively (total $30,068).

Key Details

Transaction date: March 31, 2026. Withholding price: $5.70 (Organon closing share price on March 30, 2026, per filing).
Grant: 183,639 RSUs (each RSU represents the contingent right to one share). Vesting schedule: three equal installments on Mar 31 of 2027, 2028 and 2029 (see footnote F2).
Vesting/conversion: Prior RSU grants vested on Mar 31, 2026 (6,201 and 12,312 shares converted to shares per F4–F5).
Tax withholding: 5,275 shares surrendered to cover taxes, total withholding value $30,068 (reported as dispositions under code F).
Shares owned after the transactions: not specified in the Form 4 filing.
Filing timeliness: No late filing is indicated in the provided filing information.

Context

Transaction codes: A = award/grant (RSUs); M = exercise/conversion of derivative (RSU conversion to shares); F = payment of exercise price or tax liability (share withholding to cover taxes).
The RSU grant is not an open-market purchase (it's a compensation award). The converted RSUs and the withholding are routine administrative actions to reflect vesting and tax obligations, not an open-market buy or sell signal.

Form 4

Period: 2026-03-31

Gen. Counsel & Corp. Secy.

Transactions

Exercise/Conversion
Common Stock
2026-03-31+6,201→ 85,602.163 total
Tax Payment
Common Stock
[F1]
2026-03-31$5.70/sh−1,767$10,072→ 83,835.163 total
Exercise/Conversion
Common Stock
2026-03-31+12,312→ 96,147.163 total
Tax Payment
Common Stock
[F1]
2026-03-31$5.70/sh−3,508$19,996→ 92,639.163 total
Award
Restricted Stock Units
[F2]
2026-03-31+183,639→ 183,639 total
→ Common Stock (183,639 underlying)
Exercise/Conversion
Restricted Stock Units
[F3][F4]
2026-03-31−6,201→ 0 total
→ Common Stock (6,201 underlying)
Exercise/Conversion
Restricted Stock Units
[F3][F5]
2026-03-31−12,312→ 24,625 total
→ Common Stock (12,312 underlying)

Footnotes (5)

[F1]The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted.
[F2]On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
[F3]Each RSU represents a contingent right to receive one share of Organon common stock.
[F4]On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.
[F5]On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

Signature

/s/ Tarnetta V. Jones, as Attorney-in-Fact for Kirke Weaver|2026-04-02

1 file